Loading clinical trials...

UNKNOWNPHASE3

Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure

NCT02961478•University Hospital, Angers

Summary

IOXSOR study's purpose to determine the frequency of non resolutive renal failure (estimated by the clearance of iohexol) at end of stay in ICU patients who have had acute renal failure episode.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•ICU stay \> 7 days
•Having presented during the stay renal failure stage 2 or 3 Kidney Disease Improving Global Outcomes (KDIGO)
•Steady improvement of renal function before the ICU discharge :
•* Creatinine before ICU discharge \<110 µmol / L for women, \<130 µmol / L for men
•* No recourse to extra renal purification
•* Change in creatinine levels (ΔCréatinine) less than 20% over two measures spaced 24 hours within 48 hours preceding the discharge
•Expected discharge ICU within 48 hours :
•* Glasgow score \> 13
•* Lack of mechanical ventilation except home Noninvasive Mechanical Ventilation (NiMV)
•* Lack of use of catecholamine
+2 more criteria

Exclusion Criteria

•Iohexol administration within 48 hours preceding the potential inclusion (imaging examination with X-ray contrast medium injection)
•Iohexol administration planned within 24 hours after potential inclusion in the study
•Known medical history of immediate allergic or delayed skin allergic reaction to injection of iodinated contrast material or any serious doubt on this medical history
•Patient receiving from extra renal purification during ICU discharge
•Chronic renal disease known (creatinine\> 110 µmol / L for women,\> 130 µmol / L for men) or creatinine clearance estimated less than 60 mL / min
•Pregnancy or breastfeeding women
•Patient under guardianship or safeguard justice known at the time of inclusion
•Patient limitation care
•Person not affiliated or not the beneficiary of a social security scheme

Locations (5)

University Hospital

Angers, France

Hospital center

Chartres, France

Hospital

Le Mans, France

University Hospital

Poitiers, France

University Hospital

Tours, France

Key Dates

Start Date

February 10, 2017

Primary Completion Date

June 1, 2020

Completion Date

December 1, 2020

Last Updated

March 19, 2019

Enrollment

150

ESTIMATED participants

Conditions

Acute Renal Failure

Interventions

IOHEXOL

DRUG

Contacts

François BELONCLE, CCU-AH

CONTACT

0241353845 Francois.Beloncle@chu-angers.fr

Nicolas LEROLLE, MD PhD

CONTACT

0241353845 NiLerolle@chu-angers.fr

Kidney Precision Medicine Project

NCT04334707

Acute Kidney FailureAcute Kidney Insufficiency+12 more

View study

TERMINATEDPHASE3

I.D.E.A.L.-I.C.U. (Initiation of Dialysis EArly Versus deLayed in Intensive Care Unit)

NCT01682590

Septic ShockAcute Renal Failure (as Defined by the "Failure" Stage of the RIFLE Classification)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 19, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure

Inclusion Criteria

Exclusion Criteria

Kidney Precision Medicine Project

I.D.E.A.L.-I.C.U. (Initiation of Dialysis EArly Versus deLayed in Intensive Care Unit)

SafeBoosC-IIIv - Does Cerebral Oximetry Monitoring Affect Renal Outcomes

A Post-Market Clinical Performance and Safety Evaluation of GamCath HighFlow Dolphin Protect Catheter

Inferior Vena Cava Collapsibility and Distensibility Assessment in Critical Care.

Effectiveness of the NephroCheck™ After TAVI